Bottom line
XLV vs SWHFX: the short answer
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and SWHFX (Schwab Health Care Fund) share a meaningful slice of their top holdings — about 76% by weight.
XLV is cheaper at 0.08% vs 0.8% — a difference of $72 a year per $10,000 invested.
Over five years, XLV returned +8.1% a year vs +6.5% for SWHFX.
Updated Nov 19, 2026
XLV vs SWHFX side by side
| XLV | SWHFX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | SPDR (State Street) | Schwab |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.08% | 0.8% |
| Annual cost per $10k | $8 | $80 |
| 10-yr cost on $10k (prospectus) | $103 | $990 |
| Max front load | None | — |
| 12b-1 fee | 0.02% | 0% |
| 1-yr return | +14.5% | +15.9% |
| 5-yr return (annualized) | +8.1% | +6.5% |
| 10-yr return (annualized) | +9.8% | +8.1% |
| Best quarter | +14.5% | +15.3% |
| Worst quarter | −12.7% | −12.1% |
| Net assets (fund) | $40.6B | $642.3M |
| Number of holdings | 65 | 80 |
| Portfolio turnover | 2% | 41% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | XLV | SWHFX | Difference |
|---|---|---|---|
| 2025 | +14.5% | +15.9% | −1.4% |
| 2024 | +2.5% | +0.1% | +2.4% |
| 2023 | +2.0% | +0.7% | +1.3% |
| 2022 | −2.1% | −4.7% | +2.6% |
| 2021 | +25.9% | +23.3% | +2.6% |
| 2020 | +13.3% | +12.9% | +0.4% |
| 2019 | +20.7% | +17.6% | +3.0% |
| 2018 | +6.3% | +4.0% | +2.3% |
| 2017 | +21.7% | +20.2% | +1.5% |
| 2016 | −2.8% | −4.4% | +1.5% |
Source: Fund prospectus bar charts
Holdings overlap
17 of XLV's top 25 holdings also appear in SWHFX's top 25.
| Holding | XLV | SWHFX |
|---|---|---|
| Eli Lilly & Co | 16.51% | 13.92% |
| Johnson & Johnson | 10.64% | 6.94% |
| AbbVie Inc | 7.74% | 5.81% |
| UnitedHealth Group Inc | 6.57% | 4.74% |
| Merck & Co Inc | 5.52% | 4.98% |
| Amgen Inc | 3.40% | 2.58% |
| Thermo Fisher Scientific Inc | 3.24% | 2.16% |
| Abbott Laboratories | 2.75% | 1.60% |
| Gilead Sciences Inc | 2.73% | 3.24% |
| Vertex Pharmaceuticals Inc | 2.19% | 1.89% |
| Danaher Corp | 2.09% | 1.47% |
| Bristol-Myers Squibb Co | 2.05% | 2.44% |
| Stryker Corp | 1.89% | 2.11% |
| Medtronic PLC | 1.75% | 2.29% |
| Elevance Health Inc | 1.46% | 1.45% |
Source: SEC Form N-PORT
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
SWHFX top 10
- Eli Lilly & Co — 13.92%
- Johnson & Johnson — 6.94%
- AbbVie Inc — 5.81%
- Merck & Co Inc — 4.98%
- UnitedHealth Group Inc — 4.74%
- Gilead Sciences Inc — 3.24%
- Novartis AG — 2.92%
- Amgen Inc — 2.58%
- Bristol-Myers Squibb Co — 2.44%
- Medtronic PLC — 2.29%
FAQ
What is the difference between XLV and SWHFX?
Which is cheaper, XLV or SWHFX?
Should I own both XLV and SWHFX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.